Abstract：Objective To explored the relationship between the 5-HTTLPR gene polymorphism and the therapeutic effect of Fluoxetine in the treatment of diabetic peripheral neuropathic pain.M ethods 48 patientswith diabetic peripheral neuropathic pain in ourhospital from January 2014 toMay 2015were selected and given Fluoxetine treatment for 8weeks. The PCR technology was used to examine the 5-HTTLPR gene polymorphism.Results There were 7,15 and 26 cases in L/L,L/S and S/S genotypes,respectively.The scores of SF-MPQ were(18.3±3.9)points,(22.8±4.6)points,and(25.4±5.4) points after treatment of L/L,L/S and S/S patients,compared with the scores of(45.3±5.2)points,(44.8±6.1)points and (45.7±4.9)points before treatment,respectively,with significant difference(P＜0.05).The corresponding reductions of SFMPQ was(26.2±3.7)points,(21.1±4.3)points and(20.6±5.1)points,respectively,and there was significant difference between after treatment and before treatment(P＜0.05).The reduction rate of L/L and L/Sgenomeweremore than 50％, and the reduction rate of L/L genotype was higher than that the other two genomes,with significant difference(P＜0.01). Conclusion 5-HTTLPR gene polymorphism may be associated with the effect of Fluoxetine in the treatment of diabetic peripheral neuropathic pain.
World Health Organization.Diabetes[EB/OL].http：//www.who. int/mediacentre/factsheets/fs312/en/.Accessed May 2，2009.
[2]
Argoff CE，Cole BE，Fishbain DA，et al.Diabetic peripheral neuropathic pain：clinical and quality-of-life issues[A]// Mayo Clinic Proceedings[C].Elsevier，2006.
[3]
李毅.度洛西汀治疗糖尿病周围神经病变性疼痛的疗效研究[D].重庆：重庆医科大学，2014.
[5]
Freeman R，Durso-DeCruz E，Emir B.Efficacy，safety，and tolerability of Pregabalin treatment for painful diabetic Peripheral neuropathy findings from seven randomized，controlled trials across a range of doses[J].Diabetes Care，2008，31（7）：1448-1454.
京公网安备 11010502046607号